The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension

Introduction

The intersection of oncology and cardiology has long been defined by the cardiovascular toxicities of chemotherapeutic agents. However, recent research suggests that the relationship between malignancy and vascular disease may be more deeply rooted in shared genetic vulnerabilities and systemic inflammatory pathways. A landmark study published in Circulation (2026) by Toro and colleagues investigates the reciprocal association between breast cancer and pulmonary arterial hypertension (PAH), specifically focusing on the role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2). This research provides a paradigm-shifting look at how breast cancer might act as a physiological second hit that unmasks latent pulmonary vascular disease.

Highlights

The following key findings emerge from this comprehensive study:
1. Genetic Overlap: BMPR2 expression is significantly reduced in human breast tumors, characterized by recurrent somatic variants and deep deletions.
2. Synergistic Pathogenesis: In animal models, breast cancer development exacerbated pulmonary hypertension through increased vascular remodeling and systemic inflammation.
3. Mechanistic Driver: The tumor-associated IL-1β/NF-κB axis was identified as a primary driver of pulmonary arterial smooth muscle cell (PASMC) proliferation in the presence of BMPR2 deficiency.
4. Epidemiological Bidirectionality: Clinical data reveals that breast cancer incidence is doubled in patients with PAH, while PAH incidence is nearly nine-fold higher in breast cancer survivors compared to the general population.

Background: The Gender Paradox in PAH and Breast Cancer

Pulmonary arterial hypertension and breast cancer share a striking demographic similarity: both disproportionately affect women. While PAH is a rare, devastating disease characterized by progressive pulmonary vascular resistance and right heart failure, breast cancer remains the most common malignancy among women globally.

BMPR2 mutations are well-established as the most common genetic cause of heritable PAH. Under normal physiological conditions, BMPR2 signaling maintains vascular homeostasis by inhibiting the proliferation of smooth muscle cells. However, BMPR2 also functions as a tumor suppressor in various tissues, including the breast. Despite these known roles, the functional link between BMPR2-mediated tumor suppression and pulmonary vascular health remained poorly understood until now. Researchers hypothesized that the systemic environment created by a breast tumor might trigger the clinical manifestation of PAH in individuals with a pre-existing (latent) BMPR2 vulnerability.

Study Design: A Multi-Omic and Epidemiological Approach

To explore this connection, the research team employed a sophisticated translational framework:

Bioinformatic and Genomic Analysis

The study mined large-scale human cancer datasets (such as TCGA) to identify somatic BMPR2 alterations in breast cancer patients. This allowed the researchers to determine the prevalence of BMPR2 loss in malignant tissue compared to healthy controls.

In Vivo Modeling

Using female Bmpr2+/Δ71 rats—a model of BMPR2 haploinsufficiency—the team assessed the development of spontaneous mammary tumors. They also used the carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) to induce tumors and subsequently monitored pulmonary hemodynamics and vascular morphology.

In Vitro Cellular Assays

Pulmonary arterial smooth muscle cells (PASMCs) from both rats and humans (carrying BMPR2 mutations) were exposed to tumor-conditioned media. This was done to observe the paracrine effects of tumor-derived factors on vascular cell proliferation.

Epidemiological Validation

The researchers utilized the French National Healthcare Database, analyzing records from 9,964 patients with PAH to determine the incidence of breast cancer and vice versa, providing real-world context to their experimental findings.

Key Results: Somatic BMPR2 Loss and the Second Hit Hypothesis

The results of the study provide compelling evidence for a shared molecular vulnerability. Bioinformatic analysis revealed that BMPR2 expression is markedly reduced in human breast tumors. Beyond germline mutations, the study found recurrent somatic variants and deep deletions of BMPR2 within the tumors themselves, suggesting that the loss of this receptor is a frequent event in breast oncogenesis.

In the animal models, Bmpr2+/Δ71 rats exhibited a higher frequency of spontaneous mammary tumors. When these rats were exposed to the carcinogen DMBA, they didn’t just develop tumors; they also developed significantly more severe pulmonary hypertension. These tumor-bearing rats showed advanced vascular remodeling and heightened inflammation compared to non-tumor-bearing controls. This suggests that the presence of the tumor acts as a physiological stressor—a second hit—that pushes a subclinical vascular deficiency into a clinically evident disease state.

Mechanistic Insights: The IL-1β/NF-κB Axis

A central discovery of the study is the role of inflammation in mediating this link. Tumor-bearing Bmpr2+/Δ71 rats displayed elevated levels of Interleukin-1 beta (IL-1β) and increased activation of the NF-κB pathway in their lung tissue.

In vitro experiments confirmed that conditioned media from Bmpr2-deficient tumors induced rapid proliferation of PASMCs. Crucially, this effect was IL-1β-dependent. When researchers neutralized IL-1β using specific antibodies, the proliferative response was significantly attenuated. Furthermore, human PASMCs carrying BMPR2 mutations showed a similarly heightened sensitivity to IL-1β. This suggests that the systemic inflammatory milieu created by a breast tumor directly exacerbates pulmonary vascular remodeling in individuals with BMPR2 deficiency.

Epidemiological Evidence: A Reciprocal Risk

The clinical data from the French National Healthcare Database was perhaps the most striking aspect of the study. The researchers found a bidirectional relationship:
1. Breast Cancer in PAH: Patients with a primary diagnosis of PAH had more than double the incidence of breast cancer compared to the general population.
2. PAH in Breast Cancer: Patients with breast cancer had a nearly 9-fold increase in the incidence of PAH.

This data suggests that the association is not merely a side effect of cancer treatment (such as radiation or specific chemotherapies) but rather a fundamental biological link between the two conditions.

Expert Commentary: Clinical Implications for Cardio-Oncology

The discovery of a reciprocal association between breast cancer and PAH has profound implications for clinical practice. Traditionally, if a breast cancer patient developed shortness of breath, clinicians might first look for pulmonary embolisms or cardiotoxicity from anthracyclines or HER2-targeted therapies. This study suggests that clinicians should also maintain a high index of suspicion for PAH, particularly in patients with a family history of vascular disease or known BMPR2 variants.

Furthermore, the role of IL-1β as a mediator opens new avenues for therapeutic intervention. Anti-inflammatory therapies targeting the IL-1β pathway, which are already being explored in cardiovascular medicine (e.g., the CANTOS trial), might have a dual benefit in this specific patient population—inhibiting tumor progression while simultaneously protecting the pulmonary vasculature.

However, the study is not without limitations. While the rat model provides strong mechanistic evidence, human PAH is multifactorial. The epidemiological data, while robust, may be influenced by increased medical surveillance in cancer survivors, potentially leading to a higher detection rate of asymptomatic PAH. Further prospective studies are needed to determine if screening for pulmonary hypertension should be standardized for certain subgroups of breast cancer patients.

Conclusion

The research by Toro et al. identifies BMPR2 as a shared molecular vulnerability that links breast cancer and pulmonary arterial hypertension. By acting as a source of systemic inflammation and IL-1β, breast cancer can unmask a latent susceptibility to PAH in individuals with BMPR2 deficiency. This bidirectional relationship underscores the need for integrated care models in cardio-oncology and highlights the potential for targeted anti-inflammatory strategies to mitigate vascular risk in cancer patients.

References

Toro V, Mougin M, Brossat C, et al. Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension. Circulation. 2026 Feb 17;153(7):516-533. doi: 10.1161/CIRCULATIONAHA.125.079067. Epub 2026 Jan 28. PMID: 41603037.